|
Standish M. Fleming was a co-founder of Forward Ventures, which today manages over $340 million in funds. As President and CEO of Forward Ventures Services Corporation, Fleming directs the firm's operations and guides investment strategies. He also currently serves as a Director of Arizeke Pharmaceuticals, EndiCOR, MitoKor, Nereus Pharmaceuticals, Tandem Medical and Triangle Pharmaceuticals. Before establishing Forward Ventures II, he served as start-up Chairman, President, and CEO of GeneSys Therapeutics, Forward's first portfolio company. Fleming has also served as President and/or Founding Board Member of ten companies, including Actigen (now Corixa), CombiChem, GenQuest, Nereus Pharmaceuticals, Triangle Pharmaceuticals, AITRIA, Gryphon Sciences, Ciphergen Biosystems, First Dental Health and Arizeke Pharmaceuticals. Fleming earned his M.B.A. from the UCLA Graduate School of Management and his B.A. from Amherst College. | 